Opportunistic Infections Citation List:
April 30- May 13, 2010
OPPORTUNISTIC PROTOZOA COMPOUNDS (including pneumocystis, cryptosporidium, toxoplasma, microsporidia [encephalitozoon, enterocytozoon, vittaforma])
1. Action of a Pentacyclic Triterpenoid, Maslinic Acid, against Toxoplasma gondii. De Pablos, L.M., G. Gonzalez, R. Rodrigues, A. Garcia Granados, A. Parra, and A. Osuna. J Nat Prod. [Epub ahead of print]; PMID[20441162].
[Pubmed]. OI_0430-051310.
ANTIFUNGAL COMPOUNDS ( includes Cryptococcus, Aspergillus, Candida, & Histoplasma)
2. Antimicrobial activity of phenolic acids against commensal, probiotic and pathogenic bacteria. Cueva, C., M.V. Moreno-Arribas, P.J. Martin-Alvarez, G. Bills, M.F. Vicente, A. Basilio, C.L. Rivas, T. Requena, J.M. Rodriguez, and B. Bartolome. Res Microbiol. [Epub ahead of print]; PMID[20451604].
[Pubmed]. OI_0430-051310.
3. Synthesis and the selective antifungal activity of 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives. Ozdemir, A., G. Turan-Zitouni, Z. Asim Kaplancikli, G. Iscan, S. Khan, and F. Demirci. Eur J Med Chem. 45(5): p. 2080-4; PMID[20106559].
[Pubmed]. OI_0430-051310.
4. Structure-based rational design, synthesis and antifungal activity of oxime-containing azole derivatives. Xu, Y., C. Sheng, W. Wang, X. Che, Y. Cao, G. Dong, S. Wang, H. Ji, Z. Miao, J. Yao, and W. Zhang. Bioorg Med Chem Lett. 20(9): p. 2942-5; PMID[20362444].
[Pubmed]. OI_0430-051310.
ANTIBACTERIAL COMPOUNDS (includes Mycobacterium spp., Drug Resistant, MAC, MDR)
5. Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data. Angeby, K.A., P. Jureen, C.G. Giske, E. Chryssanthou, E. Sturegard, M. Nordvall, A.G. Johansson, J. Werngren, G. Kahlmeter, S.E. Hoffner, and T. Schon. J Antimicrob Chemother. 65(5): p. 946-52; PMID[20332195].
[Pubmed]. OI_0430-051310.
6. Pt(II) and Ag(I) complexes with acesulfame: crystal structure and a study of their antitumoral, antimicrobial and antiviral activities. Cavicchioli, M., A.C. Massabni, T.A. Heinrich, C.M. Costa-Neto, E.P. Abrao, B.A. Fonseca, E.E. Castellano, P.P. Corbi, W.R. Lustri, and C.Q. Leite. J Inorg Biochem. 104(5): p. 533-40; PMID[20149461].
[Pubmed]. OI_0430-051310.
7. Activity of Scottish plant, lichen and fungal endophyte extracts against Mycobacterium aurum and Mycobacterium tuberculosis. Gordien, A.Y., A.I. Gray, K. Ingleby, S.G. Franzblau, and V. Seidel. Phytother Res. 24(5): p. 692-8; PMID[19827032].
[Pubmed]. OI_0430-051310.
8. Inhibitory properties of selected South African medicinal plants against Mycobacterium tuberculosis. Green, E., S. Amidou, L.C. Obi, P.O. Bessong, and R.N. Ndip. J Ethnopharmacol. [Epub ahead of print]; PMID[20447452].
[Pubmed]. OI_0430-051310.
9. Synthesis and antitubercular activity of heterocycle substituted diphenyl ether derivatives. Kini, S.G., A. Bhat, Z. Pan, and F.E. Dayan. J Enzyme Inhib Med Chem. [Epub ahead of print]; PMID[20443682].
[Pubmed]. OI_0430-051310.
10. Bioactive diterpenes from the aerial parts of Anisochilus harmandii. Lekphrom, R., S. Kanokmedhakul, and K. Kanokmedhakul. Planta Med. 76(7): p. 726-8; PMID[19950052].
[Pubmed]. OI_0430-051310.
11. A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis. Luckner, S.R., N. Liu, C.W. am Ende, P.J. Tonge, and C. Kisker. J Biol Chem. 285(19): p. 14330-7; PMID[20200152].
[Pubmed]. OI_0430-051310.
12. Inhibition of Mycobacterial Growth by Plumbagin Derivatives. Mathew, R., A.K. Kruthiventi, J.V. Prasad, S.P. Kumar, G. Srinu, and D. Chatterji. Chem Biol Drug Des. [Epub ahead of print]; PMID[20456370].
[Pubmed]. OI_0430-051310.
13. Structure-activity relationship of new anti-tuberculosis agents derived from oxazoline and oxazole benzyl esters. Moraski, G.C., M. Chang, A. Villegas-Estrada, S.G. Franzblau, U. Mollmann, and M.J. Miller. Eur J Med Chem. 45(5): p. 1703-16; PMID[20116900].
[Pubmed]. OI_0430-051310.
14. The anti-cancer, anti-inflammatory and tuberculostatic activities of a series of 6,7-substituted-5,8-quinolinequinones. Mulchin, B.J., C.G. Newton, J.W. Baty, C.H. Grasso, W.J. Martin, M.C. Walton, E.M. Dangerfield, C.H. Plunkett, M.V. Berridge, J.L. Harper, M.S. Timmer, and B.L. Stocker. Bioorg Med Chem. 18(9): p. 3238-51; PMID[20363637].
[Pubmed]. OI_0430-051310.
15. Synthesis and evaluation of SQ109 analogues as potential anti-tuberculosis candidates. Onajole, O.K., P. Govender, P.D. van Helden, H.G. Kruger, G.E. Maguire, I. Wiid, and T. Govender. Eur J Med Chem. 45(5): p. 2075-9; PMID[20149497].
[Pubmed]. OI_0430-051310.
16. Thiosemicarbazones, semicarbazones, dithiocarbazates and hydrazide/hydrazones: anti-Mycobacterium tuberculosis activity and cytotoxicity. Pavan, F.R., S.M.P.I. da, S.R. Leite, V.M. Deflon, A.A. Batista, D.N. Sato, S.G. Franzblau, and C.Q. Leite. Eur J Med Chem. 45(5): p. 1898-905; PMID[20163897].
[Pubmed]. OI_0430-051310.
17. Synthesis of some novel 2-substituted-5-[isopropylthiazole] clubbed 1,2,4-triazole and 1,3,4-oxadiazoles as potential antimicrobial and antitubercular agents. Suresh Kumar, G.V., Y. Rajendraprasad, B.P. Mallikarjuna, S.M. Chandrashekar, and C. Kistayya. Eur J Med Chem. 45(5): p. 2063-74; PMID[20149496].
[Pubmed]. OI_0430-051310.
18. Synthesis and antituberculosis activity of some N-pyridyl-N'-thiazolylhydrazine derivatives. Turan-Zitouni, G., Z.A. Kaplancikli, and A. Ozdemir. Eur J Med Chem. 45(5): p. 2085-8; PMID[20149489].
[Pubmed]. OI_0430-051310.
19. Conformationally-constrained indeno[2,1-c]quinolines--a new class of anti-mycobacterial agents. Upadhayaya, R.S., S.V. Lahore, A.Y. Sayyed, S.S. Dixit, P.D. Shinde, and J. Chattopadhyaya. Org Biomol Chem. 8(9): p. 2180-97; PMID[20401395].
[Pubmed]. OI_0430-051310.
20. Novel quinoline and naphthalene derivatives as potent antimycobacterial agents. Upadhayaya, R.S., J.K. Vandavasi, R.A. Kardile, S.V. Lahore, S.S. Dixit, H.S. Deokar, P.D. Shinde, M.P. Sarmah, and J. Chattopadhyaya. Eur J Med Chem. 45(5): p. 1854-67; PMID[20137835].
[Pubmed]. OI_0430-051310.
21. Design, synthesis, biological evaluation and computational investigation of novel inhibitors of dihydrofolate reductase of opportunistic pathogens. Bag, S., N.R. Tawari, M.S. Degani, and S.F. Queener. Bioorg Med Chem. 18(9): p. 3187-97; PMID[20363634].
[Pubmed]. OI_0430-051310.
22. Killing of non-replicating Mycobacterium tuberculosis by 8-hydroxyquinoline. Darby, C.M. and C.F. Nathan. J Antimicrob Chemother. [Epub ahead of print]; PMID[20435781].
[Pubmed]. OI_0430-051310.
23. Function-oriented synthesis of simplified caprazamycins: discovery of oxazolidine-containing uridine derivatives as antibacterial agents against drug-resistant bacteria. Ii, K., S. Ichikawa, B. Al-Dabbagh, A. Bouhss, and A. Matsuda. J Med Chem. 53(9): p. 3793-813; PMID[20405928].
[Pubmed]. OI_0430-051310.
24. Novel cathelicidin-derived antimicrobial peptides from Equus asinus. Lu, Z., Y. Wang, L. Zhai, Q. Che, H. Wang, S. Du, D. Wang, F. Feng, J. Liu, R. Lai, and H. Yu. FEBS J. 277(10): p. 2329-39; PMID[20423460].
[Pubmed]. OI_0430-051310.
Citations from the ISI Web of Knowledge Listings for O.I.
25. Synthesis and biological evaluation of biguanide and dihydrotriazine derivatives as potential inhibitors of dihydrofolate reductase of opportunistic microorganisms. Bag, S., N.R. Tawari, S.F. Queener, and M.S. Degani. Journal of Enzyme Inhibition and Medicinal Chemistry. 25(3): p. 331-339; ISI[000276866900006].
[WOS]. OI_0430-051310.
26. Utiliztion of the Suzuki Coupling to Enhance the Antituberculosis Activity of Aryloxazoles. Moraski, G.C., S.G. Franzblau, and M.J. Miller. Heterocycles. 80(2): p. 977-988; ISI[000276939500029].
[WOS]. OI_0430-051310.
27. A Facile Synthesis and Discovery of Highly Functionalized Tetrahydropyridines and Pyridines as Antimycobacterial Agents. Raju, S.K., M.R. Stephen, P. Subbu, B. Debjani, Y. Perumal, and S. Dharmarajan. Chemical & Pharmaceutical Bulletin. 58(5): p. 602-610; ISI[000277019100002].
[WOS]. OI_0430-051310.
28. Synthesis of some novel 2-substituted-5-[isopropylthiazole] clubbed 1,2,4-triazole and 1,3,4-oxadiazoles as potential antimicrobial and antitubercular agents. Kumar, G.V.S., Y. Rajendraprasad, B.P. Mallikarjuna, S.M. Chandrashekar, and C. Kistayya. European Journal of Medicinal Chemistry. 45(5): p. 2063-2074; ISI[000276695200047].
[WOS]. OI_0430-051310.
29. Characteristics of antiviral drugs, excluding antiretroviral agents: Update 2009 (Fluconazole, caspofungin, voriconazole in combination with amphotericin B). Tuset, M., E. Lopez-Sune, C. Cervera, A. Moreno, J.M. Miro, A. Kalkanci, M. Dizbay, N. Sari, B. Yalcin, I. Fidan, D. Arman, and S. Kustimur. Enfermedades Infecciosas y Microbiologia Clinica. 5(2): p. 194-197; ISI[000276740900012].
[WOS]. OI_0430-051310.